Download m measles, mumps, rubella vaccine, live: mmr-ii

MEASLES, MUMPS, RUBELLA VACCINE, LIVE: MMR-II
Class: Vaccine
Dosage Forms. Lyophilized Powder for Subcutaneous Injection: 0.5 mL after reconstitution with supplied diluent; also
available in combination with varicella vaccine Common FDA Label Indication, Dosing, and Titration.
1. Prevention of measles, mumps, and rubella infections: Adults, one dose (second dose indicated for adults who are at high
risk); Children, one dose at age 12 mo with a second dose at age 4-6 y, prior to entering school
Off-Label Uses. None
Drug Characteristics: Measles, Mumps, Rubella Vaccine, Live
Pregnancy Category
C
ADME
None known
Lactation
Generally considered safe during
lactation
Pharmacogenetics
Not yet clinically relevant
Contraindications
Hypersensitivity to MMR vaccine
or a component of the vaccine (egg,
gelatin, neomycin); immunosuppression;
pregnancy
Black Box Warnings
None
Merck pictured
Medication Safety Issues: Measles, Mumps, Rubella Vaccine, Live
Suffixes
Tall Man Letters
Do Not Crush
High Alert
Confused Names
MMR-II, MMRV
No
No
No
None
Drug Interactions: Measles, Mumps, Rubella Vaccine, Live
Typical Agents
Mechanism
Clinical Management
Moderate- to high-dose corticosteroids
Immunosuppression
Delay MMR vaccine administration until corticosteroid therapy has been
discontinued
Immunosuppressing agents
Immunosuppression
Delay MMR vaccine administration until immunosuppressive therapy has
been discontinued
Immune globulin or blood products
Interference with immune
response to live vaccines
Delay MMR vaccine administration for a period of time depending on type
and dose of immune globulin or blood product
172
M
Adverse Reactions: Measles, Mumps, Rubella Vaccine, Live
Common (>10%)
Less Common (1-10%)
Rare but Serious (<1%)
Fever, arthralgia (adult females)
Rash
Thrombocytopenia, anaphylaxis, Guillain-Barré syndrome, febrile seizure
Efficacy Monitoring Parameters. Prevention of measles, mumps, and rubella infections; although antibody concentrations might be measured, routine
measurement for vaccine response is not recommended.
Toxicity Monitoring Parameters. Syncope within 15 min of vaccine administration.
Key Patient Counseling Points. Some children may experience mild fever and rash 7-10 d after vaccine administration. Avoid pregnancy for 28 d following vaccine administration.
Clinical Pearls. Individuals born before 1957 can be considered immune unless a female of childbearing potential. Administer to females found to be
seronegative to rubella following completion of pregnancy. If not administered simultaneously, MMR must be separated by at least 4 wk from other live
vaccines. Individuals vaccinated between 1963 and 1967 with killed measles vaccine should be revaccinated. Individuals vaccinated before 1979 with
inactivated mumps vaccine should be revaccinated. Avoid confusion with MMRV, which also contains varicella vaccine.
172